Get the Stockscreener App
136.68
2.57%
3.43
Pre-market:
138.45
1.77
+1.29%
Davita Inc stock is traded at $136.68, with a volume of 746.80K.
It is up +2.57% in the last 24 hours and down -3.17% over the past month.
DaVita is the largest provider of dialysis services in the United States, boasting market share of about 35% when measured by clinics. The firm operates over 3,000 facilities worldwide, mostly in the US, and treats about 280,000 patients globally each year. Government payers dominate US dialysis reimbursement. DaVita receives about two thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business. Berkshire Hathaway owns about 45% of DaVita.
See More
Previous Close:
$133.25
Open:
$133.95
24h Volume:
746.80K
Relative Volume:
0.92
Market Cap:
$9.77B
Revenue:
$12.82B
Net Income/Loss:
$936.34M
P/E Ratio:
12.73
EPS:
10.74
Net Cash Flow:
$1.47B
1W Performance:
+3.48%
1M Performance:
-3.17%
6M Performance:
-11.80%
1Y Performance:
-10.18%
1-Day Range:
$133.26
$137.43
1-Week Range:
$132.69
$137.43
52-Week Range:
$126.07
$179.60
Davita Inc Stock (DVA) Company Profile
Name
Davita Inc
Sector
Industry
Phone
310-536-2668
Address
2000 16TH STREET, DENVER, CO
Compare DVA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DVA
Davita Inc
|
136.68 | 9.68B | 12.82B | 936.34M | 1.47B | 10.74 |
|
HCA
Hca Healthcare Inc
|
402.69 | 92.61B | 72.70B | 6.88B | 7.29B | 23.79 |
|
THC
Tenet Healthcare Corp
|
178.03 | 15.20B | 20.69B | 2.40B | 1.55B | 15.62 |
|
FMS
Fresenius Medical Care Ag Adr
|
24.98 | 14.72B | 20.92B | 666.06M | 1.85B | 1.1422 |
|
EHC
Encompass Health Corp
|
122.14 | 12.13B | 5.51B | 494.70M | 386.40M | 4.84 |
|
UHS
Universal Health Services Inc
|
182.56 | 11.36B | 16.08B | 1.20B | 1.06B | 17.82 |
Davita Inc Stock (DVA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-06-24 | Initiated | Barclays | Equal Weight |
| Aug-07-23 | Upgrade | UBS | Neutral → Buy |
| Nov-01-22 | Downgrade | Deutsche Bank | Buy → Hold |
| Oct-31-22 | Downgrade | UBS | Buy → Neutral |
| Aug-19-22 | Resumed | UBS | Buy |
| Jun-21-22 | Reiterated | BofA Securities | Underperform |
| Sep-10-21 | Initiated | Cowen | Market Perform |
| Aug-12-21 | Downgrade | Barclays | Overweight → Equal Weight |
| Mar-26-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Jan-05-21 | Downgrade | BofA Securities | Buy → Neutral |
| Jan-24-20 | Upgrade | Goldman | Neutral → Buy |
| Nov-07-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Oct-25-19 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Sep-11-19 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jul-26-19 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jan-08-19 | Upgrade | UBS | Sell → Neutral |
| Jan-03-19 | Initiated | Deutsche Bank | Buy |
| Dec-14-18 | Initiated | Barclays | Overweight |
| Nov-28-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Nov-16-18 | Initiated | UBS | Sell |
| Nov-08-18 | Downgrade | Raymond James | Strong Buy → Mkt Perform |
| Sep-13-18 | Upgrade | JP Morgan | Underweight → Neutral |
| Jan-04-18 | Upgrade | BofA/Merrill | Neutral → Buy |
| Dec-12-17 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-11-17 | Upgrade | Citigroup | Neutral → Buy |
| Dec-07-17 | Upgrade | Raymond James | Outperform → Strong Buy |
| Nov-08-17 | Reiterated | RBC Capital Mkts | Sector Perform |
| Oct-09-17 | Downgrade | JP Morgan | Neutral → Underweight |
| Jun-26-17 | Downgrade | Jefferies | Buy → Hold |
| Dec-13-16 | Downgrade | Robert W. Baird | Outperform → Neutral |
View All
Davita Inc Stock (DVA) Latest News
DaVita Inc. stock outperforms competitors on strong trading day - MarketWatch
Stock Analysis | DaVita OutlookMixed Signals as Technical and Fundamental Models Remain in Wait-and-See Mode - AInvest
Should DaVita's (DVA) Major Buybacks and Revenue Growth Prompt a Closer Look From Investors? - simplywall.st
What makes DaVita Inc. stock price move sharplyJuly 2025 Sector Moves & Verified Swing Trading Watchlist - thegnnews.com
Reversal Traders Monitor DaVita Inc. for EntryJuly 2025 PreEarnings & Weekly Consistent Profit Watchlists - classian.co.kr
Truist Reduces PT on DaVita Inc. (DVA) from $170 to $164; Zacks Keeps ‘Hold’ Rating - MSN
Can DaVita Inc. scale operations efficiently2025 AllTime Highs & Expert Curated Trade Setup Alerts - classian.co.kr
DaVita Inc. (NYSE:DVA) Q3 2024 Earnings Call Transcript - MSN
What’s the beta of DaVita Inc. stockBuy Signal & Risk Controlled Daily Plans - newsyoung.net
Nearly a million patients hit by DaVita dialysis ransomware attack - Kurt the CyberGuy
Watch for Bullish Crossover in DaVita Inc.2025 Top Gainers & Safe Capital Growth Plans - sundaytimes.kr
2 Warren Buffett Stocks to Buy Hand Over Fist and 1 to Avoid - The Motley Fool
How DaVita Inc. stock performs during market volatilityJuly 2025 Highlights & Technical Pattern Alert System - thegnnews.com
Will DaVita Inc. Benefit From Sector Tailwinds2025 Trading Volume Trends & Reliable Intraday Trade Alerts - newsyoung.net
DaVita’s SWOT analysis: resilient dialysis provider faces treatment growth hurdles By Investing.com - Investing.com South Africa
DaVita’s SWOT analysis: resilient dialysis provider faces treatment growth hurdles - Investing.com Canada
Resistance Break Could Fuel DaVita Inc. RallyJuly 2025 Weekly Recap & AI Driven Stock Movement Reports - metal.it
Is DaVita’s (DVA) Aggressive Buyback Amid Profit Decline a Shift in Capital Allocation Strategy? - simplywall.st
DaVita Inc. Pullback Analyzed — Is It Time to ExitQuick Gain Stock Watch With Indicators Reviewed - 선데이타임즈
DaVita’s Q2 Earnings Call: Our Top 5 Analyst Questions - Yahoo Finance
DaVita Inc. (DVA) Stock Decline & Market AnalysisNews and Statistics - IndexBox
Here's Why DaVita HealthCare (DVA) is a Strong Value Stock - Yahoo Finance
Do Wall Street Analysts Like DaVita Stock? - Yahoo Finance
Office-based Labs Market Is Going to Boom | Major Giants DaVita, Mednax, Philips, GE Healthcare - openPR.com
Are Investors Undervaluing DaVita (DVA) Right Now? - Yahoo Finance
DaVita (DVA) Is Down 6.5% After Cyber Disruption and Lowered Outlook for US Treatment Volumes - simplywall.st
Can DaVita’s (DVA) Share Buybacks Offset Mixed Q2 Earnings Trends? - simplywall.st
DaVita Inc. (DVA) Stock Forecasts - Yahoo Finance
DaVita Inc. (NYSE:DVA) Q2 2025 Earnings Call Transcript - MSN
DaVita price target lowered to $148 from $164 at Truist - TipRanks
Can DaVita Inc. be the next market leaderStock Radar with High Payoff - thegnnews.com
DaVita Healthcare's Resilient Q2 Earnings Amid Cyber Incident and Elevated Mortality Rates - AInvest
Barclays Updates DaVita (DVA) with Lower Price Target to $160 | - GuruFocus
DaVita Healthcare’s Resilient Earnings Call Amid Challenges - TipRanks
DaVita Shares Plunge 9% Amid 150% Volume Surge to $430M, Rank 264th in Market Activity - AInvest
DaVita 2025 Q2 Earnings Net Income Falls 8.2% Despite Revenue Growth - AInvest
DaVita Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
DaVita Outpaces Expectations Despite Cyberattack And Hurricane Setbacks - Finimize
DaVita Stock Down Despite Q2 Earnings Beat, Gross Margin Expands - The Globe and Mail
DaVita Inc. Stock Dives 8.5% on Declining Treatment Volumes and Forecast CutNews and Statistics - IndexBox
Why DaVita (DVA) Stock Is Nosediving - TradingView
Huge healthcare breach sees nearly a million patients hit following DaVita ransomware attackmake sure you're safe - TechRadar
Barclays Adjusts DaVita Price Target to $160 From $169 - MarketScreener
DaVita stock hits 52-week low at $131.09 amid market fluctuations - Investing.com Nigeria
Over 900K hit by DaVita ransomware hack - SC Media
DaVita 2025 Q2 Earnings Mixed Performance as Net Income Falls 8.2% - AInvest
Deutsche Bank Adjusts DaVita Price Target to $137 From $165, Maintains Hold Rating - MarketScreener
DaVita Inc. Exceeds Expectations with Strong Q2 2025 Revenue GrowthNews and Statistics - IndexBox
DaVita reiterates $2.01B–$2.16B adjusted operating income guidance for 2025 as cost controls offset volume headwinds - MSN
DaVita HealthCare: Q2 Earnings Snapshot - Greenwich Time
DaVita Inc (DVA) Q2 2025 Earnings Call Highlights: Navigating Challenges with Resilience and ... - Yahoo Finance
Davita Inc Stock (DVA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.80%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):